Company Email Format Management

Casma Therapeutics

Biotechnology Research Cambridge, Massachusetts, United States 11 employees

Employees: 11
Contacts: 3
Emails: 3
Phones: 3

casmatx.com LinkedIn Crunchbase

Casma Therapeutics Overview

Headquarters: Cambridge, Massachusetts, United States
Website: casmatx.com
Industry: Biotechnology Research
Employees: 11
Founded: 2018
Funding: 46.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

in cellular degradation

About Casma Therapeutics

Built on deep expertise in cellular degradation biology, Casma Therapeutics is advancing targeted therapies that engage the lysosomal or autophagy systems to selectively degrade disease targets and halt or reverse disease progression in neurodegeneration, oncology, inflammation, and metabolic disorders. Casma’s first-in-class TRPML1 agonist restores lysosomal function to treat Gaucher's disease patients with Parkinson's disease, and is poised to expand into GBA-associated Parkinson’s disease and idiopathic Parkinson’s disease. Casma’s PHLYTTM degrader platform is unlocking new therapeutic possibilities through selective autophagy-targeted degradation of large, complex disease targets such as organelles, protein aggregates, and signaling complexes.

Casma Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 3; 75.0% coverage

Casma Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Jennifer Cygan	Biotech Leader - Startup Advisor	San Francisco Bay Area, United States	Email Phone
Dan Baird	Vice President Molecular Discovery	Cambridge, Massachusetts, United States	Email Phone
Kou Qin, Phd	Investment Director @ Eisai Innovation	Cambridge, Massachusetts, United States	Email Phone
Nagesh Mahanthappa	Biotechnologist with a Commitment		View